Latin America Patient Derived Xenografts/PDX Models Market (2025-2030)
The Latin America Patient Derived Xenografts/PDX Models Market was valued at $7.1 Million in 2025 and projected to reach to $10.1 Million by 2030, representing a compound annual growth rate of CAGR 7.2%. Latin America's PDX Models market is positioned for sustained growth driven by increasing healthcare modernization and oncology research investments.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America Patient Derived Xenografts/PDX Models Market Trends and Insights
- Latin America's PDX market growth is driven by increasing adoption of personalized medicine approaches and rising investment in oncology research infrastructure across the region.
- Latin America represents a developing but strategically important segment within the global PDX landscape, with pharmaceutical and biotechnology companies increasingly establishing research partnerships and contract research organization (CRO) capabilities throughout the region. Latin America's 7.2% compound annual growth rate reflects the region's gradual but consistent advancement in preclinical research capabilities and cancer drug development.
- Latin America is witnessing growing demand for PDX models as pharmaceutical companies seek cost-effective alternatives to traditional xenograft models while maintaining scientific rigor.
- The forecast period through 2030 indicates Latin America will continue to capture market share as healthcare institutions and research centers invest in advanced tumor modeling technologies and expand their oncology pipelines..
Key Market Statistics
- CAGR (2025-2030) CAGR 7.2%
- Market Size, 2025 ~USD 7.1 Million
- Forecast, 2030 ~USD 10.1 Million
- Geography Latin America
Latin America Patient Derived Xenografts/PDX Models Market Overview
Market Valuation Growth :
Latin America's PDX Models market is valued at $7.1 million in 2025, with a projected CAGR of 7.2% through 2030, reaching $10.1 million. This steady growth outpaces several developed European markets and reflects increasing regional investment in precision oncology.
Personalized Medicine Adoption :
Rising adoption of personalized medicine approaches across Latin America is driving PDX model demand. Healthcare institutions are increasingly recognizing the value of patient-derived xenografts for tailored cancer treatment strategies and drug efficacy testing.
Oncology Research Infrastructure :
Significant investment in oncology research infrastructure across Latin America is expanding PDX capabilities. Government initiatives and private sector funding are establishing specialized research centers equipped with advanced xenograft modeling technologies.
Emerging Market Potential :
Latin America represents a developing but promising market for PDX models. Brazil and Mexico lead regional adoption, with growing pharmaceutical partnerships and clinical research collaborations accelerating market penetration and technology transfer.
Latin America Patient Derived Xenografts/PDX Models Market Dynamics
- The region's pharmaceutical and biotech sectors are progressively adopting patient-derived xenograft technologies to enhance drug development pipelines and personalized cancer treatment protocols.
- Brazil and Mexico are emerging as key growth hubs, supported by expanding research institutions and collaborative partnerships with global pharmaceutical companies. The market outlook remains positive as Latin American healthcare systems prioritize precision medicine initiatives and clinical trial infrastructure development.
- Government support for biomedical research, coupled with rising cancer incidence rates, will continue to fuel PDX model adoption.
- However, market growth may be tempered by limited access to advanced laboratory facilities in certain regions and cost constraints.
- Strategic partnerships between regional research centers and international biotech firms are expected to accelerate market expansion through 2030..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Latin America's PDX market is valued at $7.1 million in 2025 and expected to grow to $10.1 million by 2030, representing a 7.2% CAGR.
- Latin America is emerging as a cost-effective hub for PDX model development, attracting international pharmaceutical and biotech companies seeking research outsourcing opportunities.
- Latin America's growth is supported by increasing personalized medicine adoption and expanding oncology research infrastructure across major markets.
- Latin America's PDX market remains underpenetrated compared to developed regions, presenting significant expansion potential through 2030 and beyond.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Latin America Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical & Biotech Companies : Require Latin America-specific PDX market data to assess regional expansion opportunities, identify partnership prospects with research institutions, and optimize drug development strategies for emerging markets.
- Research & Academic Institutions : Need market intelligence on PDX adoption trends, funding availability, and infrastructure development in Latin America to benchmark capabilities, secure research grants, and establish collaborative networks.
- Healthcare & Diagnostic Service Providers : Seek regional market insights to understand personalized medicine demand, identify service expansion opportunities, and develop PDX-based diagnostic offerings tailored to Latin American healthcare systems.
- Investment & Private Equity Firms : Require comprehensive Latin America PDX market analysis to evaluate investment opportunities, assess portfolio company growth potential, and identify strategic acquisition targets in the region.
- Government & Healthcare Policy Makers : Need market data to inform oncology research funding decisions, develop precision medicine policies, and allocate resources for healthcare infrastructure improvements supporting PDX adoption across Latin America.
Key Companies in the Latin America Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Countries within Latin America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 3.64 Million |
| Mexico | USD 1.73 Million |
| Rest Of Latin America | USD 4.72 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America's PDX segment with country-level breakdowns for Brazil and Mexico, enabling targeted investment and expansion strategies in high-growth emerging markets.
- Competitive Landscape Analysis : Understand key players and market dynamics specific to Latin America's PDX ecosystem, including local research institutions, pharmaceutical partnerships, and emerging biotech companies driving regional adoption.
- Growth Driver Identification : Identify region-specific growth catalysts including personalized medicine adoption rates, oncology research funding trends, and healthcare infrastructure investments shaping Latin America's PDX market trajectory.
- Market Entry & Expansion Strategy : Develop informed go-to-market strategies for Latin America with insights on regulatory environments, reimbursement landscapes, and clinical adoption barriers across major regional markets.
- Investment Opportunity Assessment : Evaluate investment potential in Latin America's PDX sector with comprehensive analysis of market gaps, emerging opportunities, and partnership prospects with regional research and healthcare institutions.
Frequently asked questions
What is the current market size of PDX models in Latin America?
Latin America's Patient Derived Xenografts market was valued at $7.1 million in 2025 and is projected to reach $10.1 million by 2030.
What is the expected growth rate for PDX models in Latin America?
Latin America's PDX market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2030.
Why is Latin America becoming important for PDX model development?
Latin America offers cost-effective research capabilities, expanding oncology infrastructure, and growing adoption of personalized medicine, making it attractive for international pharmaceutical companies seeking outsourcing opportunities.
Which factors are driving PDX market growth in Latin America?
Key drivers include increased investment in cancer research infrastructure, rising demand for personalized medicine approaches, and growing partnerships between international biotech firms and Latin American research institutions.
How does Latin America's PDX market compare to global trends?
While Latin America's 7.2% CAGR is lower than the global 12.5% CAGR, the region represents an emerging market with significant untapped potential as research capabilities continue to develop.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report